Zepbound Medicare Advantage Coverage: What You Need to Know in 2026

Why Medicare Advantage Plans Rarely Cover Zepbound

Medicare's statutory framework has excluded anti-obesity medications from Part D formularies for over two decades. This exclusion traces back to the Social Security Act, which classified weight-loss drugs alongside cosmetic agents and fertility drugs as non-covered categories. That single provision affects every Medicare Advantage Prescription Drug (MA-PD) plan in the country.

The Statutory Exclusion Explained

Section 1862(a)(1)(A) of the Social Security Act gave CMS the authority to exclude drugs "used for anorexia, weight loss, or weight gain" from the Part D benefit. Even though Zepbound received FDA approval for chronic weight management in November 2023, that approval did not override the statutory carve-out. MA-PD plans follow the same formulary exclusion rules as standalone Part D plans unless Congress changes the law.

How MA-PD Formularies Work

Medicare Advantage plans that include prescription drug coverage (MA-PD plans) must meet CMS minimum formulary requirements. They can add drugs beyond the minimum, but they cannot add drugs in excluded categories without explicit CMS authorization. A 2024 KFF analysis found that fewer than 2% of MA-PD plans offered any supplemental anti-obesity medication benefit, and those that did imposed strict prior authorization and quantity limits.

Exceptions for Diabetes Indications

Here is the critical distinction. Tirzepatide is marketed as both Zepbound (obesity) and Mounjaro (type 2 diabetes). If a Medicare beneficiary has a documented type 2 diabetes diagnosis, their MA-PD plan will likely cover Mounjaro, because GLP-1 receptor agonists for diabetes are a protected class under Part D. A 2023 retrospective analysis found that Medicare Part D spending on GLP-1 agonists exceeded $5.7 billion, nearly all for diabetes indications.

Legislative Efforts That Could Change Coverage

Congress has introduced multiple bills aimed at removing anti-obesity medications from the Part D exclusion list. The most prominent is the Treat and Reduce Obesity Act (TROA), which has been reintroduced in every session since 2012.

The Treat and Reduce Obesity Act (TROA)

TROA would strike anti-obesity medications from the statutory exclusion, making them eligible for Part D and MA-PD formulary inclusion. A Congressional Budget Office analysis estimated that covering anti-obesity medications under Part D could cost between $35 billion and $50 billion over ten years, depending on utilization assumptions. That price tag has been the primary obstacle to passage.

CMS Administrative Actions

CMS has signaled willingness to reinterpret existing authority. In early 2025, CMS issued guidance exploring whether anti-obesity medications prescribed for cardiovascular risk reduction (rather than weight loss per se) could qualify for Part D coverage under existing rules. This followed the SELECT trial results showing that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% (HR 0.80, 95% CI 0.72-0.90) in adults with overweight/obesity and established cardiovascular disease (N=17,604).

The SURMOUNT-MMO Angle

Eli Lilly's SURMOUNT-MMO trial is evaluating tirzepatide for cardiovascular outcome reduction in a similar population. If SURMOUNT-MMO produces positive results, Lilly could seek a cardiovascular indication for Zepbound that might sidestep the anti-obesity exclusion entirely. The trial's estimated completion date is 2027, so this pathway remains speculative for now.

What Zepbound Actually Costs Without Coverage

Without insurance, Zepbound carries one of the highest monthly price tags in the GLP-1 class. Understanding the full cost picture helps Medicare beneficiaries evaluate their options realistically.

Retail Cash Price

The average retail cash price for Zepbound is approximately $1,059 per 4-week supply, across all dose levels (2.5 mg through 15 mg). Prices vary by pharmacy. GoodRx and similar discount platforms occasionally bring the price below $1,000, but savings are modest without manufacturer involvement.

Eli Lilly's Savings Programs

Eli Lilly offers a Zepbound Savings Card that can reduce the cost to as little as $25 per month for commercially insured patients. There is a critical limitation: Medicare, Medicaid, and TRICARE beneficiaries are ineligible for manufacturer copay cards under federal anti-kickback statute provisions. This means the primary cost-reduction tool available to younger patients is off-limits for the Medicare population.

LillyDirect and Telehealth Pricing

Eli Lilly launched LillyDirect, a direct-to-patient platform, offering single-dose Zepbound vials at reduced prices. As of early 2026, single-dose vials for the 2.5 mg and 5 mg strengths were priced at approximately $399 per month, and the 10 mg and 15 mg strengths at approximately $549 per month. These prices apply regardless of insurance status, making them accessible to Medicare beneficiaries willing to pay out of pocket.

Compounded Tirzepatide

Compounded versions of tirzepatide have been available through 503A and 503B compounding pharmacies while tirzepatide appeared on the FDA drug shortage list. Average costs for compounded tirzepatide run approximately $249 per month. Two warnings apply: (1) compounded drugs are not FDA-approved finished products, and (2) when the shortage resolves, FDA enforcement against compounders producing copies of commercially available drugs typically increases. The American Association of Clinical Endocrinology (AACE) has noted that compounded peptides lack the pharmacokinetic consistency of branded products.

How to Manage Coverage If You Have Medicare Advantage

Even with the statutory exclusion, Medicare Advantage beneficiaries have several practical strategies worth exploring.

Check Your Specific Plan's Supplemental Benefits

A small number of MA-PD plans have begun offering limited anti-obesity medication coverage as a supplemental benefit, outside the standard Part D structure. During the Annual Election Period (October 15 through December 7), review the Evidence of Coverage document for any plan you are considering. Look for "weight management" or "anti-obesity medication" in the supplemental benefits section. Call the plan's member services line directly, because these benefits are not always visible in the online formulary search.

Pursue Coverage Through a Diabetes Diagnosis

If you have type 2 diabetes, your physician can prescribe Mounjaro (the same molecule, tirzepatide) under the diabetes indication. Coverage rates for Mounjaro under MA-PD plans are substantially higher. A 2024 JAMA analysis found that tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539), while also reducing HbA1c by 2.07 percentage points in SURPASS-4 (N=2,002) among patients with type 2 diabetes. Both weight and glycemic benefits occur with the same drug.

Step Therapy and Prior Authorization

Even for diabetes coverage, expect prior authorization requirements. Most MA-PD plans require documentation of:

• A confirmed HbA1c ≥7.0% or documented type 2 diabetes diagnosis
• Failure or intolerance of metformin (step therapy)
• Prescriber attestation that the medication is for glycemic control

Your prescribing physician's office will need to submit the prior authorization. Turnaround times range from 24 hours to 14 days.

Appeals Process

If coverage is denied, you have the right to a multi-level appeals process under Medicare rules. The first level is a redetermination by the plan itself, which must be completed within 7 calendar days (72 hours for expedited requests). If upheld, the appeal moves to an Independent Review Entity (IRE). CMS data shows that approximately 40% to 50% of Part D appeals are resolved in the beneficiary's favor at the IRE level.

Comparing Coverage Across Insurance Types

Coverage for Zepbound varies dramatically by payer type. Understanding where Medicare Advantage falls relative to other insurance helps contextualize the situation.

Commercial Insurance

Approximately 40% to 50% of commercial plans now include some GLP-1 coverage for obesity, though cost-sharing varies widely. Prior authorization remains nearly universal. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommended GLP-1 receptor agonists and GIP/GLP-1 receptor agonists (including tirzepatide) as first-line pharmacotherapy for adults with BMI ≥30, adding clinical weight to coverage arguments.

Medicaid

Medicaid coverage of anti-obesity medications varies by state. Some state Medicaid programs have begun covering GLP-1 agonists for weight management, while others maintain exclusions similar to Medicare's. A 2024 analysis published in Obesity found that fewer than 20 state Medicaid programs covered any anti-obesity medication.

Employer-Sponsored Plans

Large self-insured employers have been the fastest adopters of GLP-1 coverage for obesity. However, employer plan drug costs for GLP-1 agonists rose 40% year-over-year in 2024, prompting some employers to add utilization management controls or drop coverage entirely.

What the Evidence Says About Tirzepatide for Weight Loss

The clinical evidence supporting tirzepatide for weight management is among the strongest in the anti-obesity medication class.

SURMOUNT Trial Program

The SURMOUNT-1 trial (N=2,539) randomized adults with BMI ≥30 (or ≥27 with a comorbidity) to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo. At 72 weeks, mean weight loss was 15.0% (5 mg), 19.5% (10 mg), and 22.5% (15 mg) versus 3.1% for placebo [1]. The 15 mg group's result represents the largest placebo-subtracted weight loss reported for any anti-obesity medication in a phase 3 trial.

SURMOUNT-2 (N=938) studied tirzepatide specifically in adults with type 2 diabetes and obesity. Mean weight loss at 72 weeks was 12.8% (10 mg) and 14.7% (15 mg) versus 3.2% for placebo [2]. Dr. Ania Jastreboff, the SURMOUNT-1 principal investigator at Yale, stated: "These are reductions in body weight that were previously only achievable through bariatric surgery."

Safety Profile

The most common adverse events in the SURMOUNT program were gastrointestinal: nausea (24% to 33%), diarrhea (17% to 23%), and vomiting (9% to 13%). Most events were mild to moderate and occurred during dose escalation. Discontinuation due to adverse events was 4.3% to 7.1% across tirzepatide arms versus 2.6% for placebo [1]. The FDA prescribing information includes a boxed warning regarding thyroid C-cell tumors based on rodent data, though no causal link has been established in humans.

Mechanism of Action

Tirzepatide is a dual GIP/GLP-1 receptor agonist, the first in its class. It activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual mechanism is believed to produce greater weight loss than GLP-1-only agonists. A head-to-head analysis published in The Lancet suggested that the GIP component contributes to enhanced fat oxidation and energy expenditure beyond what GLP-1 activation alone achieves.

Practical Steps to Reduce Your Zepbound Costs in 2026

For Medicare beneficiaries who want to use Zepbound and lack coverage, here are concrete options ranked by typical cost savings.

Patient Assistance Programs

Eli Lilly's Lilly Cares Foundation offers free medication to qualifying patients who meet income thresholds (generally at or below 400% of the federal poverty level). Medicare beneficiaries are eligible for patient assistance programs, unlike manufacturer copay cards. Applications require prescriber involvement and income documentation. Processing takes 4 to 6 weeks.

LillyDirect Vials

Single-dose vials purchased through LillyDirect at $399 to $549 per month represent a 48% to 62% reduction from the $1,059 average retail price. No insurance is needed. This is currently the most straightforward self-pay option for Medicare beneficiaries who do not qualify for patient assistance.

Compounded Tirzepatide (With Caveats)

At roughly $249 per month, compounded tirzepatide offers the lowest price point. Verify that your compounding pharmacy operates under a state Board of Pharmacy license and follows USP 797/800 standards. Discuss this option with your prescriber, who can evaluate the risk-benefit profile for your specific situation.

Supplemental Insurance or Medicare Supplement Plans

Traditional Medigap (Medicare Supplement) plans do not cover prescription drugs at all. They supplement Original Medicare's cost-sharing for Parts A and B services only. If drug coverage is a priority, switching from a Medigap + standalone Part D combination to a comprehensive MA-PD plan with supplemental obesity benefits during the next Annual Election Period may be worth evaluating.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has noted: "The gap between the clinical evidence for these medications and the insurance coverage field is wider than for almost any other drug class. Patients should not assume that 'not covered' means 'not obtainable.'"